Basic and Clinical Observations of Mevalonate Depletion on the Mevalonate Signaling Pathway.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanistic and clinical observations without systematic search methods.
PubMed 26758946 · doi:10.2174/1874467209666160112125805
What was done
The authors reviewed basic and clinical literature regarding the biological effects of inhibiting the mevalonate signaling pathway, contrasting pharmacological HMG-CoA reductase inhibition (statins) with severe pathway disruption in genetic disorders like mevalonate kinase deficiency.
What was found
The abstract reports no numerical data or quantitative results. It describes that statin-mediated inhibition of mevalonate production lowers cholesterol and favors a reduced pro-inflammatory state, while near-complete cessation of mevalonate and downstream products induces increased inflammasome activity and severe pro-inflammatory consequences.
Why it matters
This paper outlines the dual role of mevalonate pathway modulation, highlighting how the degree of depletion dictates whether cellular outcomes are therapeutically anti-inflammatory or pathologically hyperinflammatory.
Limits
This is a narrative review with no original clinical trial data or systematic synthesis reported in the abstract. No sample sizes, quantitative estimates, or statistical comparisons are provided.
Cited by
- context Cholesterol synthesis pathways produce an essential component of the mitochondrial electron transport system.